Michael A Schwarzschild, MD, PhD

Job title:
Director, Molecular Neurobiology Laboratory
Organization:
Massachusetts General Hospital
PD Guide Terms:
Etiology
Risk Factors
Biological Features
Disease Modification
Pathogenic Mechanisms
Compensatory & Neuronal Health Mechanisms
PD Subtypes
Disease Progression
Clinical & Biological Features
Therapeutic Development
Investigative Tools
Contributions:
Published Contributions:
Why target urate in PD?
Dietary Factors
21 Sep 2009 05:26 PM EST
A recent confluence of evolutionary, laboratory, epidemiological and clinical data has identified urate or one of its determinants as a promising target in the development of neuroprotective therapy ... 
Recent Caffeinated Clues to A2A in PD
Caffeine, A2A-based therapies and Parkinson's disease
19 Mar 2010 09:08 AM EST
The almost universally appreciated psychostimulant action of caffeine relies on its blockade of adenosine A2A receptors in the basal ganglia, where their expression is greatly enriched. Indeed it was ... 
We must do better (with rasagiline so far no better than levodopa as a disease-modifying therapy?)
Results of ADAGIO trial for rasagiline suggest possible disease-modifying effect
29 Sep 2009 05:40 PM EST
These recent rasagiline data (Olanow et al., 2009) represent a laudable if not heroic effort on behalf of PD patients, but unfortunately they are inconclusive and  I believe they do not warrant ... 
Responses: 4
more